Wednesday, May 17, 2017

BRIEF-Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda

* Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda (pembrolizumab) for the treatment of advanced melanoma

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)